BHVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biohaven Ltd (BHVN) is not a strong buy for a beginner, long-term investor at this time. Despite positive insider buying trends and strong analyst support with upside potential tied to its pipeline, the company's weak financial performance, lack of recent news catalysts, and neutral technical indicators suggest waiting for a clearer entry point.
The MACD is positive but contracting, RSI is neutral at 56.805, and moving averages are converging, indicating no clear trend. The price is near the pivot level of 10.143, with resistance at 10.915 and support at 9.372.
Strong analyst ratings with multiple buy recommendations and significant price target increases. Insider buying has surged by 3226.99% over the last month, indicating confidence in the company's future.
Weak financial performance in Q4 2025 with a net income drop of -22.10% YoY and EPS down -34.59% YoY. No recent news or Congress trading data to act as a catalyst.
In Q4 2025, revenue remained at 0 with no growth, net income dropped to -145.56M (-22.10% YoY), and EPS declined to -1.21 (-34.59% YoY). Gross margin showed no improvement.
Analysts are bullish with multiple buy ratings and price targets ranging from $10 to $30. Positive sentiment is driven by the company's pipeline, particularly the potential of opakalim in focal epilepsy and BHV-1400 in IgA nephropathy.
